BioRestorative Therapies Statistics
Total Valuation
BRTX has a market cap or net worth of $9.03 million. The enterprise value is $5.44 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BRTX has 25.48 million shares outstanding. The number of shares has increased by 38.49% in one year.
| Current Share Class | 25.48M |
| Shares Outstanding | 25.48M |
| Shares Change (YoY) | +38.49% |
| Shares Change (QoQ) | +81.89% |
| Owned by Insiders (%) | 3.24% |
| Owned by Institutions (%) | 14.22% |
| Float | 24.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.23 |
| Forward PS | 4.98 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 3.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35
| Current Ratio | 2.35 |
| Quick Ratio | 2.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -241.14% and return on invested capital (ROIC) is -193.90%.
| Return on Equity (ROE) | -241.14% |
| Return on Assets (ROA) | -118.81% |
| Return on Invested Capital (ROIC) | -193.90% |
| Return on Capital Employed (ROCE) | -470.16% |
| Weighted Average Cost of Capital (WACC) | 7.58% |
| Revenue Per Employee | $25,562 |
| Profits Per Employee | -$789,756 |
| Employee Count | 14 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.81% in the last 52 weeks. The beta is 0.61, so BRTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -79.81% |
| 50-Day Moving Average | 0.26 |
| 200-Day Moving Average | 0.92 |
| Relative Strength Index (RSI) | 58.81 |
| Average Volume (20 Days) | 30,288,662 |
Short Selling Information
The latest short interest is 368,665, so 1.45% of the outstanding shares have been sold short.
| Short Interest | 368,665 |
| Short Previous Month | 644,870 |
| Short % of Shares Out | 1.45% |
| Short % of Float | 1.52% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
In the last 12 months, BRTX had revenue of $357,870 and -$11.06 million in losses. Loss per share was -$0.98.
| Revenue | 357,870 |
| Gross Profit | 329,550 |
| Operating Income | -14.23M |
| Pretax Income | -11.06M |
| Net Income | -11.06M |
| EBITDA | -14.01M |
| EBIT | -14.23M |
| Loss Per Share | -$0.98 |
Full Income StatementBalance Sheet
The company has $3.59 million in cash and n/a in debt, with a net cash position of $3.59 million or $0.14 per share.
| Cash & Cash Equivalents | 3.59M |
| Total Debt | n/a |
| Net Cash | 3.59M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 3.03M |
| Book Value Per Share | 0.12 |
| Working Capital | 2.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.82 million and capital expenditures -$79,669, giving a free cash flow of -$11.90 million.
| Operating Cash Flow | -11.82M |
| Capital Expenditures | -79,669 |
| Depreciation & Amortization | 210,598 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.90M |
| FCF Per Share | -$0.47 |
Full Cash Flow StatementMargins
| Gross Margin | 92.09% |
| Operating Margin | -3,975.00% |
| Pretax Margin | -3,089.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.49% |
| Shareholder Yield | -38.49% |
| Earnings Yield | -122.45% |
| FCF Yield | -131.76% |
Analyst Forecast
The average price target for BRTX is $8.00, which is 2,157.34% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 2,157.34% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 105.57% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 27, 2021. It was a reverse split with a ratio of 1:4,000.
| Last Split Date | Oct 27, 2021 |
| Split Type | Reverse |
| Split Ratio | 1:4,000 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
